Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://cnsj.realpennies.com
China Shuangji Cement Ltd. (OTCBB: CNSJ) (Tue, February 5th, 2008, 8:30am ET) China Shuangji Cement Ltd. ("China Shuangji" or "the Company") today announces a corporate update and an action plan for this quarter.
"The change to our corporate name and ticker symbol on November 9, 2007 marks a new direction for the Company," said China Shuangji Chairman and President Wenji Song.
China Shuangji expects to receive the audited financial statements of Shandong Zhaoyuan Shuangji Group Co., Ltd. ("SZSG") and contemplates filing the necessary Form 8-K with the Securities and Exchange Commission on a series of contractual agreements with SZSG, a domestic company registered in the People's Republic of China which is engaged in the business of manufacturing of cement products.
Mr. Song further stated, "I believe that each company has undeveloped endless potential. Looking ahead, our Company faces valuable developmental opportunities, along with many difficulties and challenges. We will execute the development strategies already approved, on the basis of the strengthening cement industry, to implement brand name effectiveness, and to expand in both the domestic and international markets. Our focus will be on leveraging the Company's strengths and stepping up business development, in order to provide the best products to our customers and as well to make Shuangji a large-scale international corporation. The Company is in the new historic development stage.
We will continue to do what is necessary to establish strong corporate governance, in order to protect the interests of the Company and all shareholders. With the support of all our shareholders, and the combined efforts of the Board of Directors, management and staff, I firmly believe that Shuangji is blessed with a very promising future."
For more info: http://cyoe.realpennies.com
CytoCore Inc. (OTCBB: CYOE) (Tue, February 5th, 2008, 6:30am ET) CytoCore Inc., the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, announced today that the U.S. Food and Drug Administration has approved the company's 510(k) submission to sell CytoCore's SoftPAP cervical cell collector. The SoftPAP collects more comprehensive and complete cervical cell specimens for Pap testing.
"CytoCore's SoftPAP cervical cell collector is a significant advance in women's health," says Robert McCullough, Jr., CytoCore's CEO. "Each year, over 2 million American women are told that their Pap test was negative when, in fact, they have early stage cervical cancer. These false negatives are frequently caused by an inadequate or incomplete sample of cervical cells. SoftPAP collects complete specimens from the cervical canal, the cervical surface and the transition zone simultaneously. There is evidence that the use of SoftPAP significantly reduces the rate of false negative Pap tests leading to earlier treatment of cervical cancer."
"Studies also demonstrate that the most common adverse events that occur during the collection of the specimen are virtually eliminated with the SoftPAP," according to Dr. Richard Domanik, President and COO. "Studies involving more than 400 cervical cell collections show a 95% reduction in bleeding and spotting which are the most frequently reported adverse events associated with collection of specimens for Pap testing."
"FDA clearance enables us to become a truly global company," says Dan McMahon, Director of Marketing. "We have been selling SoftPAP in Europe for the past few months and are negotiating distribution agreements in Latin America as well. We are in the final stages of completing the North American distribution organization and expect to be able to launch the product in the United States by the end of the first quarter."
For more info: http://ppbv.realpennies.com
Purple Beverage Company, Inc. (OTCBB: PPBV) (February 4th, 2008, 8:30am ET) Purple Beverage Company, Inc. announced that it has been chosen by Morgan & Sampson as a new entry in its roster of well-known, well-respected household brands. Morgan & Sampson USA is a multi-faceted consumer product broker whose territory encompasses the entire United States.
Backed by an 87-year history of growth and service, Morgan & Sampson USA (M&S USA) represents a wide array of products ranging from pharmaceutical items to consumables. With nine offices nationwide and an additional office in the UK, M&S USA services some of the largest chains in the country, including well-known store giants Kroger, Safeway, Albertson's, Costco, Longs Drugs and many more national retailers. M&S USA's selection of products includes such household names as Kleenex , Sunbeam , Rival , Bremner-Ralston , RyKrisp Crackers and Remington , and for these and other quality goods, M&S USA develops and implements retail placement strategies that maximize sales and economic returns for both the product manufacturer and the retailers.
"We are thrilled to be partnering with Morgan & Sampson USA as part of our national rollout strategy. They are undoubtedly one of the best and most respected consumer brand product brokers in the country," said Ted Farnsworth, Founder and CEO of Purple Beverage Company. "Along with their expertise in representing well-known brands that have been around for years, they have also been instrumental in launching new brands to the marketplace that soon become household names - a fact that excites us greatly. Although Purple has been available in select stores nationwide since the product launched in 2007, our goal has always been to bring this all-natural, healthy and fun beverage to consumers everywhere. Teaming with M&S USA means that Purple will now be as close to many consumers as the shelves of their neighborhood grocery store."
Chip Carter, Chief Executive Officer for Morgan and Sampson USA, added, "After watching Purple gain exceptional traction in the marketplace in such a short period of time, we are extremely excited to add a beverage of Purple's quality to our lineup. With the growing demand for all-natural, functional beverage alternatives, we are confident that the market is ripe for an enthusiastic Purple reception." For more information about Morgan and Sampson USA, visit www.morgansampsonusa.com/.
Purple is a unique and invigorating blend of seven of the world's most powerful antioxidant juices, including the exotic acai berry, black cherry, pomegranate, black currant, purple plum, cranberry and blueberry. Combined, these juices result in an all-natural, no-sugar added beverage that is perfect as a stand-alone drink or as part of a healthy fruit smoothie.
Purple is also quickly becoming one of the most trendy antioxidant cocktail choices in nightclubs and lounges where available, as adding alcohol to antioxidant-rich berries increases the potency of the antioxidants, a fact confirmed by researchers from the United States Department of Agriculture and by a study at Kasetsart University in Thailand.
"Purple has met with rave reviews everywhere it has launched," stated Farnsworth. "With the strength of Morgan and Sampson USA's name behind it, our scope of distribution should increase dramatically over the next 60 to 90 days, and countless additional consumers will have access to Purple."
Since debuting in select cities coast to coast in 2007, Purple has been praised by such high-profile publications as Health Magazine and Family Circle.
Purple can be found in health food stores, restaurants, delis, drug stores, supermarkets and convenience stores in select locations, including New York, Los Angeles, Miami and Hawaii. In February, it became available in select GNC stores, and look for it nationwide in early 2008. For more information, visit www.drinkpurple.com.
For more info: http://idmi.realpennies.com
IDM Pharma, Inc. (Nasdaq: IDMI) (Mon, February 4th, 2008, 4:31pm ET) IDM Pharma, Inc. today announced the Journal of Clinical Oncology (JCO) has published findings from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133), entitled "Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report from the Children's Oncology Group." The landmark clinical trial, which is the largest study completed in this disease was a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG).
The COG's findings were based on long-term follow up of 662 patients with newly diagnosed non-metastatic osteosarcoma treated in the Phase 3 trial and demonstrated that the addition of L-MTP-PE to chemotherapy following surgery resulted in statistically superior Overall Survival (OS) the first stated aim of the study.
In the past two decades, there have been no treatment advances for patients with osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
"L-MTP-PE in combination with chemotherapy has demonstrated a significant long-term overall survival advantage in the largest Phase 3 clinical trial completed in patients with osteosarcoma," said Dr. Paul Meyers, vice chair, department of pediatrics at Memorial Sloan-Kettering Cancer Center and principal investigator of the Phase 3 trial. "These results are encouraging for children and young adults with osteosarcoma, considering the lack of progress for these patients in the last 20 years."
The JCO publication highlighting long-term follow up from this study formed the basis of the recent oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), regarding the Marketing Authorization Application (MAA) for L-MTP-PE for the treatment of patients with non-metastatic, resectable osteosarcoma. Updated results from this study were previously presented at the Connective Tissue Oncology Society (CTOS) annual meeting in November 2007. In addition, the new JCO publication highlights the long-term OS data whereas a prior JCO publication in 2005 focused on an Event Free Survival (EFS) additional analysis.
"These findings of statistically superior overall survival in long-term patient follow-up validate the survival benefit offered by L-MTP-PE and underscore the desperate need for new treatments for osteosarcoma patients," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We believe these findings were critical to the recent opinion from the Committee for Medicinal Products for Human Use in Europe and are a positive step toward bringing this important treatment to the European market and potentially gaining approval in the United States."
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment